Gotrade News - US healthcare value stocks drew renewed investor attention as Morgan Stanley reaffirmed conviction in Eli Lilly's Mounjaro franchise. The vote of confidence anchored a broader rotation into defensive healthcare names trading at discounted multiples.
Hospital operators Universal Health Services and Tenet Healthcare posted strong Q1 2026 results yet remain cheap on consensus estimates. Recursion Pharmaceuticals' fresh 52-week low rounded out a mixed but opportunity-rich healthcare tape.
Key Takeaways
- Morgan Stanley reiterated bullish coverage on Eli Lilly, citing Mounjaro's durable growth outside the United States.
- UHS and THC posted double-digit earnings gains in Q1 2026 while still screening cheap versus the broader market.
- Recursion Pharmaceuticals hit a 52-week low, leaving the AI-drug-discovery story as a speculative deep-value bet.
Eli Lilly's Mounjaro Catalyst
According to The Motley Fool, Morgan Stanley reaffirmed its bullish stance on Eli Lilly. The note highlighted Mounjaro's resilient sales momentum across international markets.
Lilly's Mounjaro and Zepbound posted first-quarter sales growth of 125% and 80% respectively. Even in India, Mounjaro sales rose 10% despite cheaper local GLP-1 alternatives entering the market.
The bank flagged roughly $151 billion in potential value tied to Lilly's non-US GLP-1 footprint. That figure reframes the franchise beyond the well-known American obesity-drug narrative investors already price in.
Lilly is also developing a next-generation GLP-1 candidate that appears more effective than current Mounjaro and Zepbound shots. The pipeline depth supports the trillion-dollar market capitalization the stock now carries.
Hospital Operators and Recursion Setup
As reported by Insider Monkey, Universal Health Services posted Q1 2026 net revenues of $4.495 billion. That figure represented a 9.6% year-over-year increase across its acute care and behavioral health networks.
Net income attributable to UHS climbed to $348.7 million, or $5.65 per diluted share. EBITDA net of noncontrolling interests grew to $651.7 million from $603.9 million a year earlier.
Per Insider Monkey, Tenet Healthcare's Q1 2026 net income reached $702 million, or $8.01 per diluted share. That marked a sharp jump from $406 million in the year-ago quarter.
Tenet's adjusted EBITDA held steady at $1.162 billion as disciplined expense management offset margin pressure. Management reaffirmed full-year 2026 adjusted EBITDA guidance of $4.485 billion to $4.785 billion.
Tenet also generated $1.641 billion in operating cash flow during the quarter, returning $318 million via buybacks. The capital return underscores why analysts view Tenet Healthcare (THC) as a cheap NYSE name worth owning today.
Investors looking at hospital exposure may also pair THC with Universal Health Services (UHS) for behavioral health diversification. Both names offer earnings momentum at multiples that have lagged the broader healthcare bid.
Recursion Pharmaceuticals tells a very different story after hitting a fresh 52-week low this month. The AI-drug-discovery firm has materially lagged broader equities over the past two years.
According to The Motley Fool, Recursion still commands a $1.6 billion market value despite minimal revenue. Nvidia exited its stake last year, removing a high-profile validator from the shareholder base.
The bull case rests on partnerships with Sanofi, Roche, and Bayer that may eventually monetize the platform. The bear case is a long road to commercial drugs that limits visibility for patient capital.
Taken together, the healthcare value bid offers three distinct risk profiles for portfolio construction. Eli Lilly (LLY) anchors quality growth, UHS and THC supply defensive value, and Recursion provides asymmetric speculative upside.
Sources
- Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley And It's All About Mounjaro (The Motley Fool)
- Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? (The Motley Fool)
- Universal Health Services (UHS): Cheap NYSE Stocks to Buy According to Analysts (Insider Monkey)
- Here is Why Tenet Healthcare (THC) is One of the Cheap NYSE Stocks to Buy (Insider Monkey)
